RGNX

8.53

1.16% -0.10

Dopo l'orario di chiusura: 8.50 -0.03 -0.35%

Regenxbio Inc (RGNX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$8.63

Aprire:

$8.31

Volume 24 ore:

417.42K

Relative Volume:

0.43

Capitalizzazione di mercato:

$440.26M

Reddito:

$170.44M

Utile/perdita netta:

$-193.88M

Rapporto P/E:

-2.2722

EPS:

-3.7541

Flusso di cassa netto:

$-126.38M

1 W Prestazione:

+3.27%

1M Prestazione:

-7.68%

6M Prestazione:

-19.38%

1 anno Prestazione:

+20.99%

Intervallo 1D:

$8.10

$8.68

Intervallo di 1 settimana:

$7.58

$8.895

Portata 52W:

$5.035

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Nome

Regenxbio Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

240-552-8181

Indirizzo

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Dipendente

371

Cinguettio

@REGENXBIO

Prossima data di guadagno

2025-08-01

Ultimi documenti SEC

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RGNX Regenxbio Inc	8.53	440.26M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2025-02-11	Downgrade	Goldman	Buy → Neutral
2025-02-07	Ripresa	Raymond James	Outperform
2024-11-15	Ripresa	Morgan Stanley	Overweight
2024-10-10	Ripresa	Raymond James	Outperform
2024-06-07	Iniziato	Goldman	Buy
2024-03-11	Iniziato	H.C. Wainwright	Buy
2024-03-08	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-03-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-02-21	Ripresa	Raymond James	Outperform
2023-11-01	Iniziato	Stifel	Buy
2023-06-02	Iniziato	Robert W. Baird	Outperform
2022-06-23	Iniziato	Berenberg	Buy
2021-12-15	Iniziato	Wedbush	Neutral
2021-10-19	Ripresa	Morgan Stanley	Overweight
2021-01-06	Aggiornamento	Raymond James	Outperform → Strong Buy
2020-12-16	Iniziato	UBS	Buy
2020-06-25	Ripresa	BofA/Merrill	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2019-08-20	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Reiterato	Chardan Capital Markets	Buy
2019-06-14	Ripresa	Raymond James	Outperform
2019-06-05	Reiterato	Chardan Capital Markets	Buy
2019-02-25	Aggiornamento	Evercore ISI	In-line → Outperform
2019-02-05	Aggiornamento	Raymond James	Outperform → Strong Buy
2018-12-17	Reiterato	Chardan Capital Markets	Buy
2018-11-08	Reiterato	BofA/Merrill	Neutral
2018-08-08	Reiterato	Chardan Capital Markets	Buy
2018-07-23	Downgrade	BofA/Merrill	Buy → Neutral
2018-07-10	Reiterato	Chardan Capital Markets	Buy
2018-05-09	Reiterato	Barclays	Overweight
2018-04-09	Reiterato	Chardan Capital Markets	Buy
2018-03-12	Downgrade	Evercore ISI	Outperform → In-line
2018-02-13	Iniziato	Mizuho	Neutral
2017-11-09	Ripresa	Morgan Stanley	Overweight

Mostra tutto

Regenxbio Inc Borsa (RGNX) Ultime notizie

12:44 PM

Tangible book value per share of REGENXBIO, Inc. – SWB:RB0 - TradingView

12:44 PM

11:51 AM

RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com

11:51 AM

Apr 04, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record

Apr 04, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 04, 2026

RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 04, 2026

RGNX PE Ratio & Valuation, Is RGNX Overvalued - Intellectia AI

Apr 04, 2026

RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire

Apr 04, 2026

REGENXBIO, Inc. Class Action ReminderRobbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights - Sahm

Apr 04, 2026

Apr 03, 2026

REGENXBIO: CEO Makes Major Sale During Legal Battle While Investors Split - Bitget

Apr 03, 2026

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - ChartMill

Apr 03, 2026

REGENXBIO (RGNX) proxy: directors, PwC ratification, option-exchange votes - Stock Titan

Apr 03, 2026

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Apr 03, 2026

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Apr 03, 2026

The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra

Apr 03, 2026

Apr 02, 2026